UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PCSK9: From discovery to therapeutic applications

Archives of cardiovascular diseases, 2014-01, Vol.107 (1), p.58-66

Farnier, Michel

2014

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1489-1499

2015

Volltextzugriff (PDF)

Triglycerides and risk of atherosclerotic cardiovascular disease: An update

Archives of cardiovascular diseases, 2021-02, Vol.114 (2), p.132-139

2021

Volltextzugriff (PDF)

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Atherosclerosis, 2016-01, Vol.244, p.138-146

2016

Volltextzugriff (PDF)

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

Vascular health and risk management, 2008-10, Vol.4 (5), p.991-1000

Farnier, Michel

2008

Volltextzugriff (PDF)

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

European heart journal, 2017-08, Vol.38 (29), p.2245-2255

2017

Volltextzugriff (PDF)

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Nature genetics, 2003-06, Vol.34 (2), p.154-156

2003

Volltextzugriff (PDF)

PCSK9 inhibitors

Current opinion in lipidology, 2013-06, Vol.24 (3), p.251-258

Farnier, Michel

2013

Volltextzugriff (PDF)

Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience

Current opinion in lipidology, 2016-12, Vol.27 (6), p.597-604

Farnier, Michel

2016

Volltextzugriff (PDF)

Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study

Journal of comparative effectiveness research, 2023-04, Vol.12 (4), p.e220181-e220181

2023

Volltextzugriff (PDF)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

Cardiovascular drugs and therapy, 2020-08, Vol.34 (4), p.515-523

2020

Volltextzugriff (PDF)

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Journal of clinical lipidology, 2017-01, Vol.11 (1), p.195-203.e4

2017

Volltextzugriff (PDF)

Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey

Lipids in health and disease, 2021-05, Vol.20 (1), p.45-45, Article 45

2021

Volltextzugriff (PDF)

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

The American journal of cardiology, 2010-09, Vol.106 (6), p.787-792

2010

Volltextzugriff (PDF)

Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia

The American journal of cardiology, 2013-12, Vol.112 (12), p.1885-1895

2013

Volltextzugriff (PDF)

An evaluation of alirocumab for the treatment of hypercholesterolemia

Expert review of cardiovascular therapy, 2015-12, Vol.13 (12), p.1307-1323

Farnier, Michel

2015

Volltextzugriff (PDF)

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review

Expert review of cardiovascular therapy, 2017-12, Vol.15 (12), p.923-932

Farnier, Michel

2017

Volltextzugriff (PDF)

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

Journal of clinical lipidology, 2017-07, Vol.11 (4), p.986-997

2017

Volltextzugriff (PDF)

Risk factors and prognostic value of endotoxemia in patients with acute myocardial infarction

Frontiers in cardiovascular medicine, 2024-06, Vol.11, p.1419001

2024

Volltextzugriff (PDF)

Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

Atherosclerosis, 2011-12, Vol.219 (2), p.753-760

2011

Volltextzugriff (PDF)

Identification and characterisation of patients with statin intolerance in France

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

Journal of the American College of Cardiology, 2017-02, Vol.69 (5), p.471-482

2017

Volltextzugriff (PDF)

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia

Atherosclerosis plus, 2022-12, Vol.50, p.17-24

2022

Volltextzugriff (PDF)

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

Current cardiology reports, 2016-07, Vol.18 (7), p.65-65, Article 65

Farnier, Michel

2016

Volltextzugriff (PDF)

New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines

La Presse médicale (1983), 2018-09, Vol.47 (9), p.769-774

Farnier, Michel

2018

Volltextzugriff (PDF)

1 – 25 von 302

Suche als RSS-Feed

Aktive Filter

KollektionThieme Connect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(265)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(158)
Humans
(130)
Cardiovascular System & Cardiology
(97)
Cardiac & Cardiovascular Systems
(78)
Life Sciences
(64)
Male
(63)
Female
(62)
Middle Aged
(56)
Cardiovascular
(48)
Risk Factors
(44)
Cholesterol, Ldl - Blood
(41)
Treatment Outcome
(39)
Aged
(37)
Anticholesteremic Agents - Therapeutic Use
(35)
Cholesterol
(35)
Double-Blind Method
(35)
Cardiovascular Disease
(34)
Drug Therapy, Combination
(33)
Peripheral Vascular Disease
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PCSK9: From discovery to therapeutic applications

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Triglycerides and risk of atherosclerotic cardiovascular disease: An update

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

PCSK9 inhibitors

Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience

Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia

An evaluation of alirocumab for the treatment of hypercholesterolemia

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

Risk factors and prognostic value of endotoxemia in patients with acute myocardial infarction

Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

Identification and characterisation of patients with statin intolerance in France

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines

Aktive Filter

Suchergebnisse filtern